论文部分内容阅读
目的:探讨凋亡相关基因蛋白Bc1-2及Bax在人卵巢癌的表达及意义。方法:采用SABC免疫组化方法检测了30例卵巢癌标本中Bc1-2及Bax的表达。结果:Bc1-2及Bax在恶性、交界性及良性卵巢肿瘤的阳性率分别为46.7％、40.0％、20.0％和36.7％、60.0％、40.0％。Bcl-2及Bax表达在恶性、交界性及良性卵巢肿瘤中无明显差异(P>0.05)。早期及晚期癌中Bcl-2及Bax的表达也无明显差异(P>0.05)。卵巢癌中Bcl-2阳性病例全部属上皮性肿瘤,Bax的表达在上皮性卵巢癌Ⅰ-Ⅲ病理分级中的阳性率分别为75.0％、33.3％及20.0％,Ⅰ与Ⅲ级间差异显著(P>0.05)。结论:Bcl-2在上皮性卵巢癌中有高表达,Bax的表达与肿瘤的病理分级成反比,Bc1-2及Bax的表达与肿瘤的良恶性及临床分期无关。
Objective: To investigate the expression of Bcl-2 and Bax in human ovarian cancer and its significance. Methods: The expression of Bcl-2 and Bax in 30 specimens of ovarian cancer was detected by SABC immunohistochemistry. Results: The positive rates of Bc1-2 and Bax in malignant, borderline and benign ovarian tumors were 46.7%, 40.0%, 20.0% and 36.7%, 60.0% and 40.0%, respectively. Bcl-2 and Bax expression in malignant, borderline and benign ovarian tumors showed no significant difference (P> 0.05). There was no significant difference in the expression of Bcl-2 and Bax between early and advanced cancers (P> 0.05). The positive rate of Bcl-2 positive in ovarian cancer was all epithelial tumor. The positive rates of Bax expression in pathological grade Ⅰ-Ⅲ of epithelial ovarian cancer were 75.0%, 33.3% and 20.0%, respectively. There was significant difference between Ⅰ and Ⅲ P> 0.05). CONCLUSION: Bcl-2 is overexpressed in epithelial ovarian cancer. The expression of Bax is inversely correlated with the pathological grade of the tumor. The expression of Bcl-2 and Bax is not related to the benign and malignant tumor stage and clinical stage.